Home
Scholarly Works
Perioperative Heparin Bridging in Patients With...
Journal article

Perioperative Heparin Bridging in Patients With Mechanical Aortic Valves Undergoing Elective Surgery The AMBER Study

Abstract

Background The benefit–risk balance of perioperative low-molecular-weight heparin (LMWH) bridging in patients with bileaflet mechanical aortic valves undergoing elective procedures is uncertain. While intended to prevent thromboembolism during warfarin interruption, LMWH may increase bleeding risk without a proven efficacy benefit. Objectives This study aimed to evaluate the rates of thromboembolism and bleeding associated with different peri-operative LMWH bridging strategies compared to no bridging in this patient population. Methods In a multicenter retrospective cohort study, 553 patients requiring warfarin interruption were classified into 3 main analysis groups: preoperative and postoperative LMWH (n = 232), preoperative-only LMWH (n = 81), postoperative-only LMWH (n = 33), and no bridging (n = 207). The primary efficacy outcome was arterial thromboembolism within 30 days. Primary and secondary safety outcomes were major bleeding and clinically relevant non-major bleeding. Outcomes were analyzed with multivariable logistic regression and propensity-matched comparisons. Results Thromboembolic events were rare (<0.5%) and similar across all strategies. Compared to no bridging, full bridging was associated with significantly higher rates of major bleeding (3.0% vs 0%; P = 0.018) and any clinically relevant bleeding (9.5% vs 2.0%; P < 0.01). In multivariable models, full bridging predicted bleeding, whereas preoperative-only bridging did not. In a propensity-matched analysis, full bridging remained associated with a higher risk of any clinically relevant bleeding (10.6% vs 2.4%; P < 0.01). Conclusions Among patients with bileaflet mechanical aortic valves undergoing elective procedures, 30-day thromboembolic events were rare. Full perioperative LMWH bridging was associated with increased bleeding. While this study provides valuable real-world data, prospective clinical trials are necessary to confirm and expand upon these findings.

Authors

Godoy A; Grewal TS; Bhagirath V; Tafur A; Fontani AM; Casanegra AI; Ghorbanzadeh A; Houghton DE; Abdulrehman J; Galanaud J-P

Journal

JACC Advances, Vol. 5, No. 2,

Publisher

Elsevier

Publication Date

February 1, 2026

DOI

10.1016/j.jacadv.2025.102578

ISSN

2772-963X

Contact the Experts team